Fletcher S W
Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA, USA.
J Natl Cancer Inst Monogr. 1997(22):5-9. doi: 10.1093/jncimono/1997.22.5.
This article summarizes the issues prompting a recent NIH Consensus Conference on mammography screening for women in their forties. To date, eight randomized controlled trials of breast cancer screening have been conducted, and a reduction in breast cancer mortality has emerged after 10 to 15 years of follow-up among women offered screening in their forties. No effect appears for at least eight years, and the reason for the delay, compared to that seen in women aged 50-69, is not clear. Two possibilities include cancer-stage shift due to screening in younger women and the aging of women into their fifties during the course of screening. Possible adverse effects of screening include radiation risk, although this is low, false-negative and false-positive screening tests, and overdiagnosis due to detection of ductal carcinoma in situ (DCIS). In order to make appropriate decisions regarding mammography, women need age-related information about both the benefits and potential risks of screening.
本文总结了促使美国国立卫生研究院(NIH)近期召开关于四十多岁女性乳腺钼靶筛查共识会议的相关问题。迄今为止,已开展了八项乳腺癌筛查随机对照试验,在为四十多岁女性提供筛查后的10至15年随访中,出现了乳腺癌死亡率下降的情况。至少八年内未出现效果,与50 - 69岁女性相比,延迟的原因尚不清楚。两种可能性包括年轻女性筛查导致癌症分期改变以及筛查过程中女性步入五十岁。筛查可能的不良影响包括辐射风险(尽管很低)、假阴性和假阳性筛查结果以及因原位导管癌(DCIS)检测导致的过度诊断。为了就乳腺钼靶检查做出适当决策,女性需要有关筛查益处和潜在风险的年龄相关信息。